A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)
Phase 2
Terminated
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Registration Number
- NCT00239655
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
The purpose of this study is to test MK0812 on disease activity in patients with relapsing-remitting MS. Disease modifying activity will be assessed by measurement of brain lesions via MRI brain scans and an open label extension is offered.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
- Patients must have clinically definite relapsing-remitting MS onset within last 10 years and have had at least 1 objective clinical exacerbation in the last year OR a recent clinically isolated syndrome suggestive of MS occurring 3-12 months before screening
- Patients must be relatively healthy
Exclusion Criteria
- Patient has primary progressive MS
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Accrual rate of new GD-enhancing lesions as assessed by MRI 3 Months
- Secondary Outcome Measures
Name Time Method Volume and cumulative number of new persistent Gd-enhancing lesions 3 Months